References

1) Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun. 2003;71(2):766–773.

2) Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii Preserves the Barrier Function and Modulates the Signal Transduction Pathway Induced in Enteropathogenic Escherichia coli-Infected T84 Cells. Kaufmann SHE, ed. Infection and Immunity. 2000;68(10):5998–6004.

3) Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, Marcos Andrade Goulart E, Sales Da Cunha A. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn’s disease in remission. Scand J Gastroenterol. 2008;43(7):842–848.

4) Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/ European Society for Paediatric Infectious Diseases: Evidence-based Guidelines for the Management of acute Gastroenteritis in Children in Europe. J Pediatr Gastroenterol Nutr. 2008;46 (Suppl. 2): S81–S122.

5) Htwe K, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008;78(2):214–216.

6) Höchter W, Chase D, Hagenhoff G. Saccharomyces boulardii bei akuter Erwachsenendiarrhö. Wirksamkeit und Verträglichkeit der Behandlung. Münch Med Wschr. 1990;132:188–192.

7) Szajewska, H. Skorka, A. Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther. 2009;30(9):960–961.

8) Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134(1): e176–191.

9) Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidencebased guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132–152.

10) McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006; 101(4):812–822.

11) Fuhr R, Stahlmann R. Gastrointestinale Nebenwirkungen von Antibiotika. Der Gastroenterologe. 2006;1:173–179.

12) Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2005;22(5):365–372.
13) Micklefield G. Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea [Saccharomyces boulardii bei Antibiotika-assoziierter Diarrhö]. MMW Fortschr Med. 2014;156(1):18–22.

14) McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202– 2222.

15) Can M, Beşirbellioglu BA, Avci IY, Beker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic associated diarrhea: a prospective study. Med Sci Monit. 2006;12(4):PI19–22.

16) Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069–1079.

17) Kyriakos N, Papamichael K, Roussos A. Theodoropoulos I, Karakoidas C, Smyrnidis A, Archavlis E, Lariou K, Mantzaris GJ. A Lyophilized Form of Saccharomyces Boulardii Enhances the Helicobacter pylori Eradication Rates of Omeprazole-Triple Therapy in Patients With Peptic Ulcer Disease or Functional Dyspepsia. Hospital Chronicles. 2013;8:127–133.

18) Zojaji H, Ghobakhlou M, Rajabalinia H, Ataei E, Sherafat SJ, Moghimi-Dehkordi B and Bahreiny R. The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori: a randomized controlled trial. Gastroenterol Hepatol Bed Bench. 2013;6(Suppl 1):S99–S104.

19) Namkin K, Zardast M, Basirinejad F. Saccharomyces boulardii in Helicobacter pylori eradication in children: A randomized trial from Iran. Iran J Pediatr. 2016; 26(1): e3768. doi:10.5812/ijp.3768.

20) Kollaritsch HH, Tobüren D, Scheiner O, Wiedermann G. Prophylaxe der Reisediarrhoe. Ergebnisse einer doppelblinden, plazebokontrollierten Studie über die Wirksamkeit von Saccharomyces cerevisiae CBS 5926. Münch Med Wschr. 1988;130:671–674.

21) Akhondi-Meybodi M, Rahimian M, Salmanroghani H, Amirbeigy M, Baghbanian M, Ghelmani SY. Study of the Effect of Probiotic Saccharomyces Boulardii on the Treatment of Irritable Bowel Syndrome. J Biol Today’s World. 2014;3(7):152–156.